DaVita (NYSE:DVA) Given New $96.00 Price Target at Bank of America

DaVita (NYSE:DVA – Get Rating) had its price target hoisted by Bank of America from $86.00 to $96.00 in a research note issued to investors on Tuesday, The Fly reports.

DVA has been the topic of a number of other research reports. Truist Financial raised their price target on shares of DaVita from $84.00 to $90.00 and gave the stock a hold rating in a report on Thursday, February 23rd. Deutsche Bank Aktiengesellschaft raised their price target on shares of DaVita from $72.00 to $85.00 in a report on Thursday, February 23rd. Sanford C. Bernstein started coverage on shares of DaVita in a report on Tuesday, March 7th. They issued a market perform rating on the stock. Cowen lifted their target price on shares of DaVita from $76.00 to $90.00 and gave the company an outperform rating in a research note on Thursday, February 23rd. Finally, StockNews.com started coverage on shares of DaVita in a research note on Thursday, March 16th. They set a buy rating on the stock. One analyst has rated the stock with a sell rating, five have assigned a hold rating and two have given a buy rating to the stock. According to MarketBeat, the company currently has an average rating of Hold and a consensus target price of $96.43.

DaVita Price Performance

DVA stock opened at $100.72 on Tuesday. The company has a debt-to-equity ratio of 9.92, a quick ratio of 1.16 and a current ratio of 1.20. DaVita has a 52 week low of $65.28 and a 52 week high of $106.71. The firm’s fifty day moving average is $82.33 and its 200 day moving average is $79.10. The firm has a market cap of $9.13 billion, a P/E ratio of 17.43, a P/E/G ratio of 1.79 and a beta of 0.93.

DaVita (NYSE:DVA – Get Rating) last announced its quarterly earnings results on Monday, May 8th. The company reported $1.58 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.08 by $0.50. The business had revenue of $2.87 billion for the quarter, compared to analyst estimates of $2.84 billion. DaVita had a net margin of 4.40% and a return on equity of 77.49%. The company’s revenue was up 2.0% on a year-over-year basis. During the same quarter last year, the firm earned $1.61 EPS. Research analysts predict that DaVita will post 5.93 earnings per share for the current year.

Insider Activity at DaVita

In related news, Director Charles Berg sold 735 shares of DaVita stock in a transaction dated Wednesday, March 1st. The shares were sold at an average price of $81.78, for a total transaction of $60,108.30. Following the completion of the transaction, the director now directly owns 17,164 shares of the company’s stock, valued at approximately $1,403,671.92. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. 1.00% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

A number of large investors have recently bought and sold shares of the business. Norges Bank purchased a new position in DaVita during the 4th quarter valued at about $116,373,000. Morgan Stanley raised its holdings in DaVita by 37.9% in the fourth quarter. Morgan Stanley now owns 1,232,647 shares of the company’s stock worth $92,042,000 after buying an additional 339,051 shares during the last quarter. Lazard Asset Management LLC raised its holdings in DaVita by 8.5% in the fourth quarter. Lazard Asset Management LLC now owns 857,087 shares of the company’s stock worth $63,998,000 after buying an additional 67,216 shares during the last quarter. Amundi raised its holdings in DaVita by 226.3% in the fourth quarter. Amundi now owns 659,372 shares of the company’s stock worth $52,592,000 after buying an additional 457,285 shares during the last quarter. Finally, Charles Schwab Investment Management Inc. raised its holdings in DaVita by 4.4% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 542,905 shares of the company’s stock worth $40,539,000 after buying an additional 22,988 shares during the last quarter. 86.52% of the stock is owned by hedge funds and other institutional investors.

DaVita Company Profile

(Get Rating)

DaVita, Inc engages in the provision of medical care services. It operates through the following two segments: US Dialysis and Related Lab Services, and Other-Ancillary Services and Strategic Initiatives. The US Dialysis and Related Lab Services segment offers kidney dialysis services in the United States for patients suffering from chronic kidney failure.